FBIO Fortress Biotech, Inc. logo

FBIO Fortress Biotech, Inc.

Healthcare
$2.74-1.44%ClosedMarket Cap: $91.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

11.10

PEG

0.10

P/B

0.53

P/S

1.38

EV/EBITDA

20.64

DCF Value

$-0.81

FCF Yield

173.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

64.5%

Operating Margin

-84.4%

Net Margin

193.1%

ROE

163.9%

ROA

35.8%

ROIC

-20.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$16.0M$110.4M$
Q4 null$16.1M$-3.9M$
FY null$63.3M$6.8M$
Q3 null$17.6M$5.8M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$5.00

Target (Median)

$5.00

Target Range

$5.00 - $5.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-02-23
HC Wainwright & Co.Buy
2025-08-21

Trading Activity

Insider Trades

View All
Jin Davidofficer: Chief Financial Officer
SellWed Apr 01
WEISS MICHAEL Sdirector, officer: Executive Vice Chairman
SellFri Mar 20
ROSENWALD LINDSAY A MDdirector, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN
SellFri Mar 20
Lorenz Kevindirector
SellMon Jan 05
LOBELL J JAYdirector
SellMon Jan 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.16

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Peers